340B Drug Pricing Program
The Department of Health and Human Services today in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart the administrative process for such a program.
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart the administrative process for such a program.
Blog: 340B is a Solution, not a Threat to Health Care Affordability
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and bipartisan health care challenges.
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing Program.
Congress has passed the Consolidated Appropriations Act of 2026 (H.R.7148), which consists of a short-term continuing resolution for the Department of Homeland Security (DHS) appropriations bill and a package of five full-year appropriations bills, containing conferenced legislation for the…
- Legislation and Legislative Advocacy
- Medicaid
- Medicare
- Medicare Sequestration Payment Reductions
- Cybersecurity
- Rural issues
- Workforce
- Child and Adolescent Health
- Maternal Health
- Medical Education and Research
- Access to Behavioral Health
- Substance Use Disorder
- Disaster Preparedness
- 340B Drug Pricing Program
The AHA weighs in on a number of issues of importance to hospitals and health systems, as well as the patients they care for, as they come before the court. Below are our most recent friend-of-the-court briefs.
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and Company policy from taking effect on Feb. 1, including by “assessing civil monetary penalties for intentionally overcharging 340B hospitals.”
AHA urges HRSA to stop Eli Lilly’s new claims-data submission policy on 340B hospitals from going into effect; hospitals urged to submit their own letters to HRSA and use AHA letter as a guide.
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all dispensations of all Lilly drugs, regardless of setting.